middle.news
US FDA Clears IND for Neurotech’s NTI164, Advancing Global Development
8:50am on Tuesday 14th of July, 2026 AEST
•
Healthcare
Read Story
US FDA Clears IND for Neurotech’s NTI164, Advancing Global Development
8:50am on Tuesday 14th of July, 2026 AEST
Key Points
FDA clears IND for NTI164 clinical program in the US
US pharmacokinetic study to complement Australian Phase 3 trial
Integrated data package supports global regulatory submissions
Strengthened US patent portfolio enhances asset protection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE